⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Topotecan in Treating Children With Refractory Leukemia

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Topotecan in Treating Children With Refractory Leukemia

Official Title: TOPOTECAN FOR CHILDREN WITH REFRACTORY LEUKEMIA, A PEDIATRIC ONCOLOGY GROUP PHASE I COOPERATIVE AGREEMENT STUDY

Study ID: NCT00002705

Conditions

Leukemia

Study Description

Brief Summary: Phase I trial to study the effectiveness of topotecan in treating children with refractory leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

Detailed Description: OBJECTIVES: I. Describe the qualitative and quantitative toxic effects, including acute and chronic dose-limiting toxicity, cumulative toxicity, and time to recovery, in pediatric patients with refractory leukemia who are treated with a 30-minute daily infusion of topotecan (TOPO) for up to 12 consecutive days every 3 weeks. II. Estimate the maximum tolerated dose of TOPO that results in tolerable, predictable, and reversible toxicity. III. Determine the precautions and supportive therapy that should be used and the clinical and laboratory studies needed to monitor or alter therapy to prevent unacceptable toxicity in these patients. IV. Observe any antileukemic effects that may occur during this phase I study in which duration of treatment is increased from 7 to 9 and then 12 days and TOPO doses are escalated. V. Determine the recommended phase II pediatric dose of TOPO. VI. Characterize the pharmacokinetic parameters of TOPO and evaluate changes in these parameters with the first and last doses to determine whether there is drug accumulation. VII. Correlate, if possible, these pharmacokinetic parameters with clinical response and toxicity. OUTLINE: Single-Agent Chemotherapy. Topotecan, TOPO, NSC-609699.

Eligibility

Minimum Age:

Eligible Ages: CHILD, ADULT

Sex: ALL

Healthy Volunteers: No

Locations

University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

University of California San Diego Cancer Center, La Jolla, California, United States

Lucile Packard Children's Hospital at Stanford, Palo Alto, California, United States

Shands Hospital and Clinics, University of Florida, Gainesville, Florida, United States

Emory University Hospital - Atlanta, Atlanta, Georgia, United States

Children's Memorial Hospital, Chicago, Chicago, Illinois, United States

University of Kansas Medical Center, Kansas City, Kansas, United States

Via Christi Regional Medical Center, Wichita, Kansas, United States

MBCCOP - LSU Medical Center, New Orleans, Louisiana, United States

Johns Hopkins Oncology Center, Baltimore, Maryland, United States

Boston Floating Hospital Infants and Children, Boston, Massachusetts, United States

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Children's Hospital of Michigan, Detroit, Michigan, United States

Washington University School of Medicine, Saint Louis, Missouri, United States

Hackensack University Medical Center, Hackensack, New Jersey, United States

Roswell Park Cancer Institute, Buffalo, New York, United States

State University of New York - Upstate Medical University, Syracuse, New York, United States

Memorial Mission Hospital, Asheville, North Carolina, United States

Duke Comprehensive Cancer Center, Durham, North Carolina, United States

Saint Jude Children's Research Hospital, Memphis, Tennessee, United States

Medical City Dallas Hospital, Dallas, Texas, United States

Simmons Cancer Center - Dallas, Dallas, Texas, United States

Baylor College of Medicine, Houston, Texas, United States

San Antonio Military Pediatric Cancer and Blood Disorders Center, Lackland Air Force Base, Texas, United States

University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States

Montreal Children's Hospital, Montreal, Quebec, Canada

Hopital Sainte Justine, Montreal, Quebec, Canada

University of Puerto Rico School of Medicine Medical Sciences Campus, San Juan, , Puerto Rico

Clinique de Pediatrie, Geneva, , Switzerland

Contact Details

Name: Wayne Lee Furman, MD

Affiliation: St. Jude Children's Research Hospital

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: